PMC:7536954 / 395-606 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":22,"end":27},"obj":"Disease"},{"id":"T11","span":{"begin":131,"end":159},"obj":"Disease"},{"id":"T12","span":{"begin":140,"end":159},"obj":"Disease"},{"id":"T13","span":{"begin":161,"end":164},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0007915"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0004670"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0007915"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":22,"end":49},"obj":"http://purl.obolibrary.org/obo/PR_000000134"},{"id":"T8","span":{"begin":51,"end":54},"obj":"http://purl.obolibrary.org/obo/PR_000000134"},{"id":"T9","span":{"begin":181,"end":182},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":44,"end":49},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":22,"end":49},"obj":"Gene"},{"id":"30","span":{"begin":50,"end":57},"obj":"Gene"},{"id":"40","span":{"begin":131,"end":159},"obj":"Disease"},{"id":"41","span":{"begin":161,"end":164},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:7124"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:7124"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"MESH:D008180"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D008180"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":22,"end":27},"obj":"Phenotype"},{"id":"T7","span":{"begin":95,"end":116},"obj":"Phenotype"},{"id":"T8","span":{"begin":131,"end":159},"obj":"Phenotype"},{"id":"T9","span":{"begin":161,"end":164},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002725"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002725"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":28,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T2","span":{"begin":28,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T3","span":{"begin":28,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T4","span":{"begin":28,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"e first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use "}